Please wait while the transcript is being prepared...
0:00
My name is Joshua M. Hare, M.D.
I am a professor of medicine at
the Miller School of Medicine
at the University of Miami.
Today, I'm going to
speak to you about
cardiac stem cell therapy.
0:16
There has been a
long-standing quest to repair
the damaged heart with
cell-based therapy
that goes back to the 1990s,
at which time there were
early attempts using
skeletal myoblasts to repair
damaged hearts in
preclinical models.
In the early 2000s, investigators
turned their interest
to answering the question
of whether tissues like
the bone marrow contain
a compartment of cells with
tissue reparative properties.
Since that time there's been
an extensive amount
of work using
adult type cell-based therapy
from bone marrow and
other types of tissues.
But this has been accompanied
by very substantial controversy
over whether such cells
have true differentiation
capacity.
In other words, can
these cells engraft and
differentiate into a host
tissue like the heart?
This field however has
continued to produce
provocative data and there
are ongoing clinical
trials to this date.
The current state of
the art in the 2020s
is to explore programs
that have developed
on the earlier work
that use, for example,
combination cell
therapy, combining
different types of cells
to optimize a result,
combining cell with gene therapy
and finally, we are starting to
see the clinical development
of pluripotent stem cells,
again alone or in combination.
I will cover each of these
topics in the lecture.
Another approach
that I won't cover
in this lecture is
whether or not we can
improve tissue repair by using
tissue engineering approaches
as compared to just
cell-based therapy alone.
But the topic for today is
cell-based therapy alone.
